Skip to main content
. Author manuscript; available in PMC: 2008 Apr 7.
Published in final edited form as: Breast Cancer Res Treat. 2006 Jul 19;101(2):161–174. doi: 10.1007/s10549-006-9286-9

Figure 4. Complement-dependent cytotoxicity (CDC) of 51Cr-MCF-7 and 51Cr-PMN.

Figure 4

a) 51Cr-release assay was used to test the ability of mAb FC-2.15 (0, 2.5, 10, 20 μg/ml) to mediate CDC on 51Cr-MCF-7 and 51Cr-PMN in suspension. b) 51Cr-release assay was used to test the ability of mAb FC-2.15 (0, 2.5, 10, 20 μg/ml) to mediate CDC on 51Cr-MCF-7 and 51Cr-PMN adhered to HUVEC. c) Evaluation of the lytic effect on 51Cr-HUVEC of bound cells undergoing FC-2.15-mediated CDC. 51Cr-release assay was used to test the ability of complement alone (C') or FC-2.15 (20 μg/ml) plus complement (FC-2.15 + C') to mediate CDC when unlabeled PMN, unlabeled fMLP-activated PMN, and unlabeled MCF-7 are adhered to 51Cr-HUVEC. Data shown are mean ± SD of triplicate determinations in three independent experiments. Paired Student's t test, P<0.05. d) MCS-1 mediates CDC: MTT assay was performed on MCF-7 in suspension after treatment with mAbs FC-2.15 or MCS-1 (2.5, 10, 20 μg/ml) in the presence of C'. Control isotype-matched immunoglobulins used were IgM and IgG3. Paired Student's t test, P<0.05. Data shown are mean ± SD of triplicate determinations in three independent experiments. e) MCS-1 mediates CDC: MTT assay was performed on PMN in suspension after treatment with mAbs FC-2.15 or MCS-1 (2.5, 10, 20 μg/ml) in the presence of C'. Control isotype-matched immunoglobulins used were IgM and IgG3. Paired Student's t test, P<0.05. Data shown are mean ± SD of triplicate determinations in three independent experiments.